Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: A meta-analysis of randomized controlled trials

Internal Medicine

Volumn 48, Issue 24, 2009, Pages 2069-2076

  Yuan, Wenzhen ^a   Yang, Kehu ^a   Ma, Bin ^a   Li, Yumin ^a   Guan, Quanlin ^a   Wang, Donghai ^b   Yang, Lijuan ^a  

^a LANZHOU UNIVERSITY   (China)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Clarithromycin; First line treatment; Helicobacter pylori; Meta analysis; Moxifloxacin

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; MOXIFLOXACIN; NITROIMIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE BISMUTH CITRATE; TINIDAZOLE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UREA BREATH TEST;

AZA COMPOUNDS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; ODDS RATIO; PROTON PUMP INHIBITORS; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 74549134768     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2344     Document Type: Article

References (42)

1. Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med 160: 1285-1291, 2000.
2. Proceedings of the American Digestive Health Foundation International Update Conference on Helicobacter pylori. McLean, Virginia, USA, February 13-16, 1997. Gastroenterology 113 (6 Suppl ): S1-S169, 1997.
3. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330: 1267-1271, 1994.
4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 347: 1175-1186, 2002.
5. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789, 2001.
6. Bazzoli F. Italian omeprazole triple therapy - a 1-week regimen. Scand J Gastroenterol Suppl 215: 118, 1996.
7. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 13: 1-12, 1998.
8. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167-180, 2002.
9. Houben MH, van Beek D, Hensen EF, et al. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13: 1047-1055, 1999.
10. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115 (5): 1272-1277, 1998.
11. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53 (9): 1374-1384, 2004.
12. Megraud F, Doermann HP. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43 Suppl1 : S61-S65, 1998.
13. Ducons JA, Santolaria S, Guirao R, et al. Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer. Aliment Pharmacol Ther 13: 775-780, 1999.
14. Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 32: 763-768, 2000.
15. Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 136: 13-24, 2002.
16. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 118 (2 Suppl 1): S2-S8, 2000.
17. Tankovic J, Lascols C, Sculo Q, et al. Single and double mutations in gyrA but not in gyrB are associated with low- and highlevel fluoroquinolone resistance in Helicobacter pylori. Antimicrob Agents Chemother 47: 3942-3944, 2003.
18. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 43: 511-555, 1999.
19. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in eastern Europe. Clin Microbiol Infect 8: 388-396, 2002.
20. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46: 1029-1031, 2000.
21. Bago P, Vcev A, Tomic M, et al. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 119: 372-378, 2007.
22. Cammarota G, Cianci R, Cannizzaro O, et al. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1339-1343, 2000.
23. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 11: 46-51, 2006.
24. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 16: 527-532, 2002.
25. Di Caro S, Zocco MA, Cremonini F, et al. Levofloxacin based regimens for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 14: 1309-1312, 2002.
26. Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 12: 623-628, 2007.
27. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 1241-1247, 2005.
28. Sharara AI, Chaar HF, Racoubian E, et al. Efficacy of two rabeprazole/ gatifloxacin-based triple therapies for Helicobacter pylori infection. Helicobacter 9: 255-261, 2004.
29. ZL, XS, QS, et al. The eradication rate of H. pylori with moxifloxacin-based therapy versus standard therapy. J XINGJIANG MEDICAL UNIVERSITY 30: 141, 2007.
30. Ahuja V, Dhar A, Bal C, et al. Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 12: 551-555, 1998.
31. Gupta VK, Dhar A, Srinivasan S, et al. Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with norfloxacin, in a dual-therapy study. Am J Gastroenterol 92: 1140-1142, 1997.
32. Saad RJ, Schoenfeld P, Kim HM, et al. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 101: 488-496, 2006.
33. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12, 1996.
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 7: 177-188, 1986.
35. Kilic ZM, Koksal AS, Cakal B, et al. Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Dig Dis Sci 53: 3133-3137, 2008.
36. Chiba N. Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori. Am J Gastroenterol 91: 2139-2143, 1996.
37. Ching SS, Sabanathan S, Jenkinson LR. Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital. World J Gastroenterol 14: 3855-3860, 2008.
38. Hurduc V, Plesca D, Dragomir D, et al. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori infection in children. Acta Paediatr 98: 127-131, 2009.
39. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Grampositive organisms. Int J Antimicrob Agents 14: 45-50, 2000.
40. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20: 245-256, 2000.
41. von Keutz E, Schluter G. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 43 (Suppl B): 91-100, 1999.
42. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 64: 1893-1904, 2004.